Wonju Medical Device Industry Promotion Agency, selected as the second new project lead organization for the '2025 Industrial Innovation Base Construction Project'

The Wonju Medical Device Industry Promotion Agency (President Jong-Hyeon Han, hereinafter referred to as the 'Medical Industry Promotion Agency') has been finally selected as the main organization for the second new project of the '2025 Industrial Innovation Base Construction Project' hosted by the Ministry of Trade, Industry and Energy.

This project will be worth a total of 14.4 billion won and will be jointly carried out by a consortium of five organizations, including the Wonju Medical Device Industry Promotion Agency as the lead organization and the Korea Health Management Association.

The selected research and development project is called 'Establishment of Biodata and Algorithm Verification Base for Supporting AI-based Age-Tech Industry-centered Digital Medical Products' and is scheduled to be implemented in stages for five years starting in 2025. Through this project, the Korea Medical Industry Promotion Agency plans to create a real-use environment based on biodata and utilize this to establish an integrated support system that covers everything from AI digital medical product development to commercialization.

In particular, by providing integrated support for the entire process from data design, analysis, verification, and provision, we will build a precise verification infrastructure so that domestic digital medical device companies can proceed to actual product development as well as global approval acquisition and market entry. In addition, we plan to secure a foundation for sustainable performance creation and self-reliance by running a paid technology service model such as data analysis, algorithm verification, technology consulting, and infrastructure operation.

Wonju Medical Device Industry Promotion Agency Director Jong-Hyeon Han said, “This project will be an important stepping stone for domestic medical device companies to become globally competitive,” and added, “We will do our best to establish it as a key infrastructure for the digital medical era that combines AI and biodata.”